Advance T-Cell Engagers from Bench to Bedside
The T-Cell Engager Therapeutics Summit Europe is the first European forum dedicated to accelerating the safe and effective development of TCEs across oncology and emerging autoimmune indications. Gain actionable insights into target selection, preclinical modelling, translational strategies, and novel design formats that will shape the next generation of immunotherapies.
This interactive meeting brings together leaders in Immunology, Preclinical Development, Translational Research, Antibody Engineering, and Immuno-Oncology to address the field’s toughest challenges: optimising tumour selectivity, managing toxicity, enhancing T-cell fitness, and expanding therapeutic potential beyond oncology.
Key focus areas include next-generation design formats (masked, logic-gated, and trispecific TCEs), synergy with co-stimulation, approaches to preclinical model limitations, translation into clinical trial design, and the growing role of TCEs in autoimmune disease.
Unmissable Event Highlights
Driving Potent & Safer TCEs Through Co-Stimulation
Learn how Regeneron and Zymeworks are combining TCEs with CD28, CD137, and CD2 agonists to enhance T-cell fitness and expand cytotoxic potential. Understand how co-stimulation improves target affinity and how to select the optimal pathway for your molecule.
Next-Generation Design: Expanding the Therapeutic Window with Masked & Conditional TCEs
Hear from Xilio Therapeutics, Molecular Partners, and NovalGen on advancing masked CD3-targeting molecules and autoregulated platforms. Explore how these innovative approaches minimize toxicity, safeguard against T-cell exhaustion, and extend therapeutic reach.
Exploring New Modalities: Beyond Traditional TCEs
From AstraZeneca’s TITAN nanobody-based engagers to BIOMUNEX’s MAIT cell platforms and NK cell engagers, discover how novel formats are expanding multi-targeting strategies and reshaping the future of cell engager design.
Overcoming Preclinical Barriers to Translation
Work directly with experts from Amgen, Roche and NovalGen to address key gaps in current TCE models, from hyperactivated T cells to unrealistic tumour clearance. Leave with actionable strategies to improve translatability and strengthen confidence in moving from preclinical proof-of-concept to the clinic.
Explore the Full Event Guide
- Benchmark the latest clinical and preclinical insights shaping next-generation TCE development in oncology and autoimmunity
- Translate innovative design strategies, from co-stimulation to masked and logic-gated TCEs into improved specificity, potency, and safety
- Equip yourself with solutions to overcome translational and preclinical challenges, including hyperactivated T cells and unrealistic tumour clearance models
- Connect with leading biopharma, biotech, and academic pioneers driving novel modalities such as TITAN nanobodies, MAIT engagers, and NK cell engagers
- Position your team at the forefront of emerging therapeutic opportunities, with firsthand insights into investment trends, partnerships, and expansion into autoimmune disease
Attending Companies Include
Explore the Agenda
Dive into cutting-edge T-cell engager science with insights from leading biopharma, biotech, and academic experts.
Partner With Us
Showcase your technologies and services to decision-makers driving next-generation TCE innovation.
Join Biopharma Experts
Be part of the only European meeting uniting immunology, biology, preclinical, and translational experts in the TCE space.